PATHOGENETICALLY ORIENTED CORRECTION OF PLATELET ACTIVITY, COAGULATION IMBALANCE AND ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS
Ochiq kirish: yoʻq
Annotatsiya
Rheumatoid arthritis is frequently accompanied by platelet activation, coagulation imbalance, and endothelial dysfunction, which may persist despite standard anti-inflammatory treatment. This study evaluated the effects of standard therapy and pathogenetically oriented combined therapy on platelet function, coagulation parameters, and endothelial dysfunction markers in patients with rheumatoid arthritis. Patients without adverse thrombophilia-related genotypes received either standard treatment alone or standard treatment supplemented with endothelial, antiplatelet, and anticoagulant correction, whereas patients with adverse genotypes received genotype-oriented therapy that additionally included folate correction. Platelet count, adhesion, aggregation, activated partial thromboplastin time, prothrombin index, fibrinogen, D-dimer, endothelin-1, and soluble intercellular adhesion molecule were assessed before and after treatment. Platelet count decreased after therapy but did not normalize consistently. In contrast, platelet adhesion and aggregation improved more markedly with combined therapy than with standard treatment. Among patients without adverse genotypes, adhesion decreased from 46–52 to 28–30, while aggregation decreased from 49–52 to 31–33. Activated partial thromboplastin time increased from 19.5–24.2 seconds to 30.5–38.5 seconds, fibrinogen decreased from 3.55–4.66 g/L to 2.44–3.13 g/L, and D-dimer declined from 380–460 ng/mL to 291–332 ng/mL. Endothelin-1 and soluble intercellular adhesion molecule levels also decreased more substantially after combined therapy. These findings indicate that pathogenetically oriented combined treatment provides more pronounced correction of platelet hyperactivity, hypercoagulability, and endothelial dysfunction than standard therapy alone.
Hali tarjima qilinmagan